Published in Am J Pathol on December 23, 2010
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS One (2013) 0.95
RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation. Proc Natl Acad Sci U S A (2014) 0.95
Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. Clin Cancer Res (2013) 0.94
An expression signature at diagnosis to estimate prostate cancer patients' overall survival. Prostate Cancer Prostatic Dis (2014) 0.93
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res (2013) 0.89
Investigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary game. Br J Cancer (2011) 0.88
Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth. Oncotarget (2015) 0.81
Hedgehog signaling in prostate epithelial-mesenchymal growth regulation. Dev Biol (2015) 0.81
Androgen receptor footprint on the way to prostate cancer progression. World J Urol (2011) 0.80
Development of a reactive stroma associated with prostatic intraepithelial neoplasia in EAF2 deficient mice. PLoS One (2013) 0.80
The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: a pilot study. Biomed Res Int (2015) 0.76
Stromal Hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer. Dis Model Mech (2016) 0.75
Stromal Androgen Receptor in Prostate Cancer Development and Progression. Cancers (Basel) (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev (1996) 5.17
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol (2008) 4.72
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol (2004) 4.41
Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res (2002) 3.94
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61
Histologic grading of prostate cancer: a perspective. Hum Pathol (1992) 3.36
Reactive stroma in prostate cancer progression. J Urol (2001) 3.21
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Epidemiology of prostate cancer. Urology (2003) 2.91
Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res (2003) 2.47
Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res (2009) 2.34
Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res (2002) 2.22
Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res (2002) 1.89
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol (2000) 1.89
Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol (1997) 1.86
Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res (2004) 1.77
In vitro dorsal root ganglia and human prostate cell line interaction: redefining perineural invasion in prostate cancer. Prostate (2001) 1.58
Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res (2002) 1.57
The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol (1994) 1.53
Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol (2006) 1.51
Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology (1994) 1.48
Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol (2005) 1.37
Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer (1992) 1.34
Role of stromal myofibroblasts infiltrating colon cancer in tumor invasion. Pathol Res Pract (1996) 1.29
Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol (1996) 1.29
Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys (2008) 1.27
Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol (1996) 1.26
Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate (2003) 1.26
Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.26
Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate (2005) 1.24
Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol (2001) 1.22
The role of fibroblasts in tumor behavior. Cancer Metastasis Rev (1995) 1.10
Looking beyond morphology: cancer gene expression profiling using DNA microarrays. Cancer Invest (2003) 1.07
Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J Urol (1994) 1.05
Nomograms for prostate cancer. BJU Int (2006) 1.02
Bystin in perineural invasion of prostate cancer. Prostate (2006) 1.01
Neuroepithelial interactions in prostate cancer are enhanced in the presence ofprostatic stroma. Urology (2003) 1.00
MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer (2007) 0.96
Grading prostate cancer. Am J Clin Pathol (1994) 0.95
Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer (2008) 0.95
Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol (1998) 0.94
Reprint of: Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol (2008) 0.92
Gleason histologic grading in prostatic carcinoma. Correlation of 18-gauge core biopsy with prostatectomy. Arch Pathol Lab Med (1994) 0.86
Partin tables: past and present. BJU Int (2003) 0.82
The biologic dilemma of early carcinoma of the prostate. Cancer (1996) 0.82
Staging prostate cancer--1997: current methods and limitations. Eur Urol (1997) 0.81
Treatment of PSA only recurrence of prostate cancer after prior local therapy. Curr Pharm Des (2006) 0.80
Prostate cancer outcome: epidemiology and biostatistics. Anal Quant Cytol Histol (2005) 0.78
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology (2005) 4.71
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res (2002) 3.94
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol (2013) 3.65
Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol (2013) 3.65
Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate (2003) 3.44
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res (2006) 3.32
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
Comparative effectiveness of prostate cancer surgical treatments: a population based analysis of postoperative outcomes. J Urol (2010) 3.18
Failure of bone marrow cells to transdifferentiate into neural cells in vivo. Science (2002) 3.18
Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol (2012) 3.12
Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer (2008) 3.06
Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05
Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol (2009) 3.04
The prevention of prostate cancer--the dilemma continues. N Engl J Med (2003) 3.00
Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol (2005) 2.98
Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA (2003) 2.85
MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem (2010) 2.85
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer (2005) 2.78
High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res (2004) 2.75
Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol (2007) 2.75
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2005) 2.69
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol (2003) 2.59
Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol (2008) 2.57
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2008) 2.57
An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol (2004) 2.53
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Translocation of single-stranded DNA through single-walled carbon nanotubes. Science (2010) 2.50
Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol (2006) 2.50
Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology (2005) 2.49
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell (2007) 2.48
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res (2003) 2.47
Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res (2005) 2.44
TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res (2009) 2.42
Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology (2006) 2.40
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res (2009) 2.34
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun (2013) 2.31
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol (2007) 2.30
Workgroup report: workshop on source apportionment of particulate matter health effects--intercomparison of results and implications. Environ Health Perspect (2005) 2.29
Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology (2007) 2.23
Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res (2002) 2.22
Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol (2011) 2.22
Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. Cancer (2009) 2.18
Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer. J Urol (2012) 2.15